[Skip to Content]
[Skip to Content Landing]
Global Health
May 16, 2017

Freeze-dried Rotavirus Vaccine Shows Promise

JAMA. 2017;317(19):1941. doi:10.1001/jama.2017.5482

Three doses of a live, oral bovine rotavirus pentavalent vaccine (BRV-PV) protected healthy infants in Niger from severe rotavirus gastroenteritis, reported a team of international investigators in the New England Journal of Medicine.

Rotavirus is a leading cause of diarrhea-associated hospitalization and death in children younger than 5 years around the world, with the highest death rate from this virus occurring in sub-Saharan Africa. Currently there are 2 licensed vaccines in use against rotavirus, but both require refrigeration. The BRV-PV vaccine, which was designed specifically for use in remote areas with limited electricity or health clinics, is freeze-dried, does not require refrigeration, and is thermostable for 2 years at 37°C and for 6 months at 40°C.